• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. 2022, , 1174.更正：贝努奇等人。预测非药物转换后疗效丧失：依那西普转换为SB4的患者及初治风湿性疾病患者中循环肿瘤坏死因子-α水平与SB4之间的相关性。2022年，，1174。
J Pers Med. 2023 Jan 18;13(2):168. doi: 10.3390/jpm13020168.
2
Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease.预测非药物转换后的疗效丧失：依那西普转换为SB4的患者及初治风湿性疾病患者循环肿瘤坏死因子-α水平与SB4之间的相关性
J Pers Med. 2022 Jul 19;12(7):1174. doi: 10.3390/jpm12071174.
3
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.是否切换：全国强制性从原研药切换至生物类似药依那西普的指南结果。DANBIO 登记处 2061 例炎性关节炎患者的 1 年治疗结果。
Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.
4
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching' by Cantini and Benucci.对坎蒂尼和贝努奇所著《强制、成本驱动下从原研依那西普转换为其生物类似药SB：非医学转换可能产生的影响》的回应
Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.
5
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review.关于初治或换药患者中依那西普生物类似药SB4的真实世界证据：一项系统评价
Rheumatol Ther. 2019 Sep;6(3):317-338. doi: 10.1007/s40744-019-00169-4. Epub 2019 Aug 5.
6
Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.依那西普生物类似药 SB4 维持银屑病关节炎患者低疾病活动度的疗效：一项开放性标签、为期一年的研究。
J Dermatolog Treat. 2020 Nov;31(7):687-691. doi: 10.1080/09546634.2019.1606886. Epub 2019 May 1.
7
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.从原研依那西普转换为SB4：来自关节炎症性疾病治疗耐受性和持续性真实生活经验的数据。
Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20964031. doi: 10.1177/1759720X20964031. eCollection 2020.
8
Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.依那西普生物类似药SB4在银屑病患者中的临床经验。
Int J Clin Pharm. 2019 Feb;41(1):9-12. doi: 10.1007/s11096-018-0769-7. Epub 2019 Jan 4.
9
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.类风湿关节炎患者继续使用SB4或从对照药依那西普转换为SB4的长期疗效及安全性。
Ann Rheum Dis. 2017 Nov 13;76(12):1986-1991. doi: 10.1136/annrheumdis-2017-211591.
10
Switching patients with inflammatory arthritis from Etanercept (Enbrel) to the biosimilar drug, SB4 (Benepali): A single-centre retrospective observational study in the UK and a review of the literature.将炎性关节炎患者从依那西普（恩利）转换为生物类似药SB4（贝那利单抗）：英国一项单中心回顾性观察研究及文献综述
Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):69-75. doi: 10.31138/mjr.30.1.69. eCollection 2019 Jun.

本文引用的文献

1
Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease.预测非药物转换后的疗效丧失：依那西普转换为SB4的患者及初治风湿性疾病患者循环肿瘤坏死因子-α水平与SB4之间的相关性
J Pers Med. 2022 Jul 19;12(7):1174. doi: 10.3390/jpm12071174.

更正：贝努奇等人。预测非药物转换后疗效丧失：依那西普转换为SB4的患者及初治风湿性疾病患者中循环肿瘤坏死因子-α水平与SB4之间的相关性。2022年，，1174。

Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. 2022, , 1174.

作者信息

Benucci Maurizio, Damiani Arianna, Bandinelli Francesca, Russo Edda, Li Gobbi Francesca, Grossi Valentina, Amedei Amedeo, Infantino Maria, Manfredi Mariangela

机构信息

Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, 50143 Florence, Italy.

Department of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy.

出版信息

J Pers Med. 2023 Jan 18;13(2):168. doi: 10.3390/jpm13020168.

DOI:10.3390/jpm13020168
PMID:36836609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9965674/
Abstract

The authors wish to make the following correction to this paper [...].

摘要

作者希望对本文做出如下更正

[...]